Study of newer treatments for hard-to-treat autoimmune conditions
Part of Immune system & allergy clinical trials.
This study follows people with difficult-to-treat inflammatory or autoimmune diseases to see how safe and effective newer treatments (called immunomodulators) are. It is observational, meaning the researchers will just watch and record what happens during your regular care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed inflammatory or autoimmune disease (as per standard medical criteria).
- Your disease must be active and not responding to usual treatments, so your doctor wants to try a new treatment.
- You must be enrolled in the French national health system.
- You should not have conditions like severe immunosuppression, active infections, recent cancer, or major organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to understand the immune system in people who have immune problems or whose immune-related diseases are not helped by standard treatments. It may lead to better ways to diagnose and treat these conditions.
This trial tests a new treatment for people with advanced blood cancers like leukemia or lymphoma that have come back or not improved. The goal is to see if the drug can help control the disease.
This study looks at blood “biomarkers,” or measurable body signals, in people with autoimmune diseases, vasculitis, or autoinflammatory conditions. The goal is to better understand these illnesses and how they relate to disease activity.
This trial tests a new type of medicine (ABO2203) that trains your immune system to attack the cells causing your autoimmune disease. It's for people who haven't gotten better with standard treatments.
This study tests an investigational drug called KSVCBD for people with certain autoimmune diseases that haven't improved with standard treatments. It aims to see if the drug is safe and if it can help reduce symptoms.
This study tests a new investigational drug (called ATG-201) for people with autoimmune diseases. It aims to see if the drug is safe and how it works in the body.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.